A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
DOI10.1111/J.1541-0420.2008.01119.XzbMATH Open1172.62069OpenAlexW2052806027WikidataQ45713082 ScholiaQ45713082MaRDI QIDQ3183236FDOQ3183236
Authors: Guosheng Yin, Ying Yuan 
Publication date: 19 October 2009
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.1541-0420.2008.01119.x
Recommendations
- Dose-finding with two agents in phase I oncology trials
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Bayesian dose finding for combined drugs with discrete and continuous doses
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response
tablesmaximum tolerated doseBayesian estimationGibbs samplingsynergyadaptive designtoxicityphase I trialcombining drugs
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Contingency tables (62H17)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Adaptive Rejection Metropolis Sampling within Gibbs Sampling
- Design and Analysis of Phase I Clinical Trials
- A Random Walk Rule for Phase I Clinical Trials
- Dose finding in drug development.
- Bayesian optimal designs for phase I clinical trials
- Dose finding using the biased coin up-and-down design and isotonic regression
- Designs for Single- or Multiple-Agent Phase I Trials
- Statistical Methods for Dose‐Finding Experiments
- Dose-finding with two agents in phase I oncology trials
- A Curve‐Free Method for Phase I Clinical Trials
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Two‐Dimensional Dose Finding in Discrete Dose Space
- General Models for the Joint Action of Mixtures of Drugs
- Experimental Design for Joint Action
Cited In (13)
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- Continual reassessment method for partial ordering
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Adaptive clinical trial designs for phase I cancer studies
- Dose-finding with two agents in phase I oncology trials
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
- Application of gamma process to two-agent combinations with delayed toxicity
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
This page was built for publication: A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3183236)
